Genmab — November 2017
-
Following JnJ's Q3 results and ahead of Genmab's Q3 report, we cut our near-term Darzalex forecasts (2017-20) by moderating the penetration curve. This cuts 2017E-19E EPS by 8-16% and 2020E EPS by 4%. After 2020, we make no estimate revision as we still firmly believe in Darzalex reaching up to USD ~9bn in peak sales in myeloma. Hence, the NPV effect is more moderate than our near-term EPS forecast changes. On an accumulated basis, our 2017-25 EPS forecasts are down 2.3%
-
and our DCF-derived target price faces the same cut, falling to DKK 1,480 (1,515). We believe that the recent share price slump is a significant overreaction and it provides a genuine buying opportunity ahead of sustainably strong Darzalex performance, ASH and solid cancers news flow. We reiterate our Buy rating on the share.
-
Tak jky
-
Enig Bibob - det burde det ikke i sig selv og han anbefaler jo også køb på en overreaktion (citat: a significant overreaction). Novod regner iøvrigt med 30 pct rabat i europa sammenlignet med US - og intet på solide eller Tiso - ikke ligefrem en aggressiv tilgang må man sige.
-
at least someone still writing about Ofa in CLL (which seems a lost battle?) https://www.ashclinicalnews.org/online-exclusive/adding-idelalisib-ofatumumab-improves-progression-free-survival-patients-relapsed-cll/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind